JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rutten, I.
Right arrow Articles by Hustinx, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rutten, I.
Right arrow Articles by Hustinx, R.
Journal of Nuclear Medicine Vol. 48 No. 5 720-725
© 2007 by Society of Nuclear Medicine

doi: 10.2967/jnumed.106.038216

Clinical Investigation

PET/CT of Skull Base Meningiomas Using 2-18F-Fluoro-L-Tyrosine: Initial Report

Isabelle Rutten1, Jean-Evrard Cabay2, Nadia Withofs3, Christian Lemaire4, Joel Aerts4, Veronique Baart1 and Roland Hustinx3

1 Department of Radiotherapy, C.H.U. of Liège, Liège, Belgium; 2 Department of Medical Imaging, C.H.U. of Liège, Liège, Belgium; 3 Department of Nuclear Medicine, C.H.U. of Liège, Liège, Belgium; and 4 Cyclotron Research Center, University of Liège, Liège, Belgium

Correspondence: For correspondence or reprints contact: Isabelle Rutten, MD, Department of Radiotherapy, C.H.U of Liège, B-4000 Liège, Belgium. E-mail: irutten{at}chu.ulg.ac.be

Precise delineation of the shape of skull base meningiomas is critical for their treatment and follow-up but is often difficult using conventional imaging such as CT and MRI. We report our results with PET/CT and 2-18F-fluoro-L-tyrosine (18F-TYR), a marker of amino acid transport, as part of the yearly follow-up of irradiated patients. Methods: Eleven patients (mean age, 56.5 y) with skull base meningiomas (n = 13 lesions) previously irradiated were included. All patients received 300 MBq of 18F-TYR and were imaged after 30 min of uptake, using a dedicated PET/CT system. The images were first visually examined, and regions of interest (ROI) were then placed over the transaxial PET slice showing the highest uptake. Another ROI was placed over the normal parietal cortex. Tumor-to-cortex activity ratios were obtained by dividing the maximum pixel value in the tumor ROI by the maximum pixel value in the cortex ROI. The PET/CT images were compared with the MR images obtained as part of routine follow-up. Results: Accumulation of the tracer was higher in all meningiomas than in the surrounding tissue. The tumor-to-cortex activity ratio was 2.53 ± 0.35 (range, 1.3–6). Nonneoplastic tissue such as hyperemic cavernous sinus did not take up the radionuclide and was therefore easily distinguished from the meningioma. The 18F-TYR anomalies completely overlapped with the MR image in 54% of the tumors, extended beyond the MRI lesion in 38% of the tumors, and were smaller in 8% of the tumors. Conclusion: Meningiomas of the skull base are clearly visualized using 18F-TYR PET/CT, even after irradiation. In addition to MRI, 18F-TYR PET/CT images may contribute to the evaluation, delineation, and follow-up of these tumors.

Key Words: meningioma • 2-18F-fluoro-L-tyrosine • metabolic imaging

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.